Welcome to our dedicated page for Repligen news (Ticker: RGEN), a resource for investors and traders seeking the latest updates and insights on Repligen stock.
Repligen Corporation reports business developments as a global life sciences company focused on bioprocessing technologies and systems used in manufacturing biological drugs. Its updates center on Filtration and Fluid Management, Chromatography, Process Analytics and Proteins, serving biopharmaceutical drug developers, CDMOs and other life science customers.
Recurring announcements include quarterly and annual financial results, financial guidance, organic revenue measures, margin commentary, product and support infrastructure such as Repligen Training & Innovation Centers and OPUS pre-packed chromatography columns, investor conference participation, regional customer support initiatives and board or senior finance governance changes.
Repligen Corporation (NASDAQ:RGEN) announced a definitive agreement to acquire ARTeSYN Biosolutions for approximately $200 million, enhancing its portfolio of single-use downstream bioprocessing systems. The acquisition is expected to generate around $30 million in pro forma revenue for ARTeSYN in 2020 and contribute $33 to $36 million in 2021, with breakeven adjusted earnings per share in the same year and accretive results anticipated in 2022. This move complements previous acquisitions of Engineered Molding Technologies and Non-Metallic Solutions, positioning Repligen as a leading player in the bioprocessing market.
Repligen Corporation (NASDAQ:RGEN) will announce its third quarter 2020 financial results on November 5, 2020, before the market opens. A conference call will take place at 8:30 a.m. EST to discuss the results and business updates. Investors can access the call by phone or via a webcast on the company’s Investor Relations page. Repligen is a global life sciences company focused on developing bioprocessing technologies that enhance the manufacturing of biological drugs.
Repligen Corporation (NASDAQ:RGEN) reported record quarterly revenue of $87.5 million, a year-over-year increase of 24% with 19% organic growth. The company raised its fiscal year revenue guidance to $332-$340 million, reflecting anticipated margins expansion and continued demand amid COVID-19 vaccine programs. Gross margin improved to 57.9%, with EPS rising to $0.30 from $0.17 a year ago. The acquisition of Engineered Molding Technology supports RGEN's strategic focus on expanding its single-use portfolio.
On June 15, 2020, Repligen Corporation (NASDAQ:RGEN) announced the appointment of Carrie Eglinton Manner to its Board of Directors. With over 23 years in the healthcare sector, she brings extensive leadership experience, notably as Senior VP at Quest Diagnostics and former President & CEO at GE Healthcare. Her expertise in business growth and profitability is expected to support Repligen's innovation-based strategy. The Board expressed confidence in her ability to enhance company operations and expand its market presence in bioprocessing technologies.
Repligen Corporation (NASDAQ:RGEN) reported record Q1 2020 revenue of $76.1 million, a 25% increase year-over-year, driven by 16% organic growth. The company achieved a GAAP gross margin of 58.0%, with GAAP EPS of $0.18. Adjusted EPS rose to $0.32, reflecting strong demand in gene therapy and chromatography sectors. The company maintains its 2020 revenue guidance of $309-$319 million, projecting a 14%-18% overall growth. Optimistic outlook amid COVID-19 efforts, focusing on employee safety while maintaining operational stability.